Pulse Biosciences (NASDAQ:PLSE) Trading 2% Higher - Here's Why

Key Points

• Pulse Biosciences shares rose 2% during trading, reaching a high of $15.09, with a significant increase in trading volume compared to the average.
• Oppenheimer initiated coverage with an "outperform" rating and a target price of $22.00 for Pulse Biosciences, indicating potential growth.
• Institutional investors collectively own 76.95% of Pulse Biosciences, with notable increases in stakes from major names like Vanguard Group and Deutsche Bank.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report)'s stock price rose 2% on Thursday . The company traded as high as $15.09 and last traded at $15.02. Approximately 217,195 shares were traded during trading, an increase of 53% from the average daily volume of 142,021 shares. The stock had previously closed at $14.73.

Analyst Upgrades and Downgrades

Separately, Oppenheimer initiated coverage on Pulse Biosciences in a research note on Monday, July 7th. They issued an "outperform" rating and a $22.00 price target for the company.

Pulse Biosciences Stock Up 0.3%

The business has a fifty day simple moving average of $15.81 and a 200-day simple moving average of $17.14.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.25) earnings per share for the quarter.

Insider Transactions at Pulse Biosciences

In related news, CTO Darrin Uecker sold 15,000 shares of Pulse Biosciences stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $16.40, for a total transaction of $246,000.00. Following the sale, the chief technology officer owned 137,872 shares of the company's stock, valued at approximately $2,261,100.80. This trade represents a 9.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 71.50% of the company's stock.

Hedge Funds Weigh In On Pulse Biosciences

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Pulse Biosciences by 15.1% during the 4th quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company's stock valued at $19,958,000 after acquiring an additional 150,506 shares during the period. Bank of America Corp DE boosted its holdings in Pulse Biosciences by 0.4% during the 4th quarter. Bank of America Corp DE now owns 788,454 shares of the company's stock valued at $13,727,000 after acquiring an additional 2,884 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Pulse Biosciences by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 460,768 shares of the company's stock worth $8,024,000 after buying an additional 3,603 shares during the period. Invesco Ltd. lifted its holdings in shares of Pulse Biosciences by 1,956.7% in the 4th quarter. Invesco Ltd. now owns 214,490 shares of the company's stock worth $3,734,000 after buying an additional 204,061 shares during the period. Finally, Westside Investment Management Inc. lifted its holdings in shares of Pulse Biosciences by 5.5% in the 1st quarter. Westside Investment Management Inc. now owns 58,155 shares of the company's stock worth $936,000 after buying an additional 3,034 shares during the period. Institutional investors own 76.95% of the company's stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.